HER-2/neu Oncogene Amplification in Breast Cancer
Author Information
Author(s): J.J. Pavy, F. Descotes, G.L. Adessi
Primary Institution: CHU Jean Minjoz
Hypothesis
What is the relationship between HER-2/neu oncogene amplification and various clinical parameters in breast cancer?
Conclusion
HER-2/neu amplification is associated with poor prognosis indicators in breast cancer.
Supporting Evidence
- HER-2/neu amplification was found in 16.6% of the breast cancer samples.
- Statistically significant associations were observed between HER-2/neu amplification and PR content in specific patient subsets.
- The study highlighted discrepancies in previous literature regarding HER-2/neu amplification associations.
Takeaway
This study looked at a gene called HER-2/neu in breast cancer to see if it could help doctors understand how serious the cancer is. They found that when this gene is amplified, it usually means the cancer is worse.
Methodology
The study assessed the relationship between HER-2/neu amplification and clinical factors using slot and Southern blotting techniques.
Potential Biases
The categorization of continuous variables may introduce bias, and the methods used may not account for tumor heterogeneity.
Limitations
The study's statistical methods were not perfect, and the choice of cut-off values may have influenced the results.
Participant Demographics
The study included a non-selected population of breast cancer patients.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website